Research programme: nuclear receptor modulators - Vitae Pharmaceuticals

Drug Profile

Research programme: nuclear receptor modulators - Vitae Pharmaceuticals

Alternative Names: AGN193198

Latest Information Update: 11 Jan 2011

Price : $50

At a glance

  • Originator Allergan
  • Class Small molecules
  • Mechanism of Action Cytoplasmic and nuclear receptor modulators; Retinoic acid receptor agonists; Retinoic acid receptor antagonists; Retinoid X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Neutropenia

Most Recent Events

  • 24 Mar 2008 NRX 4204 has moved into clinical development
  • 18 May 2007 Vitae Pharmaceuticals sublicenses rights to this research programme to Quest Group International
  • 16 Aug 2005 Preclinical trials in Neutropenia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top